SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): December 1, 2008
BIOPHAN
TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-26057
|
82-0507874
|
|
(State
or Other Jurisdiction of Incorporation or Organization)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
15
Schoen
Place, Pittsford, New York 14534
(Address
of principal executive offices) (Zip Code)
Copies
to:
Gregory
Sichenzia, Esq.
Andy
Smith, Esq.
Sichenzia
Ross Friedman Ference LLP
61
Broadway
New
York,
New York 10006
Phone:
(212) 930-9700
Fax:
(212) 930-9725
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item
8.01. Other Events
At
the
Company’s annual shareholder meeting on September 12, 2008, shareholders were
asked to approve a proposal to amend the Company’s Articles of Incorporation to
increase the number of authorized shares of common stock to 800,000,000. The
meeting was adjourned with regard to this proposal until December 1, 2008
(subject for further adjournment by those attending the reconvened meeting)
or
such earlier date as the Company obtains sufficient votes to approve this
proposal. At the reconvened meeting on December 1, 2008, the meeting was further
adjourned until February 4, 2009 (subject for further adjournment by those
attending the reconvened meeting) or such earlier date as the Company obtains
sufficient votes to approve this proposal.
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
| |
|
|
| |
BIOPHAN TECHNOLOGIES, INC. |
|
|
|
| Dated:
December 5, 2008 |
By: |
/s/ John
Lanzafame |
| |
Name:
John Lanzafame |
| |
Title:
Chief Executive Officer |